Abstract Details

Title Pregnancy and Multiple Sclerosis in a Spanish Tertiary Academic Hospital: A Prospective Analysis of 36 Patients

Topic MS and Related Diseases

Presentation(s) P02 - (-)

Poster/Presentation
Number 132

Objective

Background BACKGROUND: In Multiple sclerosis (MS) women, pregnancy has a beneficial short-term effect on inflammation and relapse rate (RR), but data regarding long term effects on disability are inconclusive.

Design/Methods DESIGN/METHODS: We assessed the reproductive history, MS history, pregnancy course and new-born outcome of a cohort of MS patients who had had a pregnancy between 2007 and 2011 in our centre. The patients had been prospectively followed in each trimester of the pregnancy and in the postpartum period. Additionally, a complementary semi-structured interview was performed. Finally, we compared the global results with a cohort of 60 age-matched healthy pregnant controls.

Results RESULTS: Complete data from 36 consecutive women were analyzed. Main age 32 Y/O (21-41), 10 patients (27,8%) didn't have a relapse in 2 years before pregnancy, 17 (47,2%) had 1 relapse, the rest (25%) had 2 o more relapses. EDSS at pregnancy: in 26 patients (72%) was 0, in 5 patients (13%) was 1, the rest (15%) >2. Delivery: 32 patients (89%), cesarean 4 (11%). Epidural anesthesia: 27 patients (75%). New-born sex: male 23 (63%), female 13 (37%). Weight: 3100 gr. (1200-3800). Two-years postpartum relapse: no relapses: 16 patients (44%), 1 relapse: 11 (30%), 2 relapses: 5 (13%), 3 relapses: 2 (13%). Main time for first relapse: 15.6 weeks (1.3-89). The comparison between RR and EDSS 2 years before-after delivery showed no statistically significant difference.

Conclusions CONCLUSIONS: Our series confirms that there are no change in the relapse rate when considering a period of 2 years before and after pregnancy, and that there is no negative impact on the progression of the disease itself after pregnancy. Our series also suggest that there is no additional morbidity in the pregnant MS patient comparing to the rest of the population.

Authors/Disclosures
PRESENTER	No disclosure on file
Maria Luisa Martinez Gines, MD	Dr. Martinez Gines has nothing to disclose.
	No disclosure on file
Clara De Andres, MD	No disclosure on file
Timothy L. Vollmer, MD, FAAN	The institution of Dr. Vollmer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen IDEC. The institution of Dr. Vollmer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech/Roche. The institution of Dr. Vollmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Siranax. The institution of Dr. Vollmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. The institution of Dr. Vollmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. The institution of Dr. Vollmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Meyers Squib. The institution of Dr. Vollmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Viela Bios. The institution of Dr. Vollmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. The institution of Dr. Vollmer has received research support from Rocky Mountain MS Center. The institution of Dr. Vollmer has received research support from Biogen. The institution of Dr. Vollmer has received research support from Actelion. The institution of Dr. Vollmer has received research support from Genentech/Roche. The institution of Dr. Vollmer has received research support from Anokion. The institution of Dr. Vollmer has received research support from TG Therapeutics.

��ɫ��

��ɫ��